Dolores J. Schendel
Chief Tech/Sci/R&D Officer bij MEDIGENE AG
Vermogen: 1 M $ op 29-02-2024
Profiel
Founder of Medigene Immunotherapies GmbH, Dolores J.
Schendel presently is Chief Scientific Officer at MediGene AG and Chief Executive Officer of Medigene, Inc. (a subsidiary of MediGene AG).
In the past Dr. Schendel occupied the position of Member-Scientific Review Board at German Cancer Aid, Managing Director at Medigene Immunotherapies GmbH, Professor at Ludwig-Maximilians-Universität München, Member-Scientific Review Board at European Research Council and Member-Scientific Review Board at Deutsche Forschungsgemeinschaft.
Dolores J.
Schendel received a doctorate from the University of Wisconsin.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
MEDIGENE AG
3.45% | 30-06-2023 | 846 296 ( 3.45% ) | 1 M $ | 29-02-2024 |
Actieve functies van Dolores J. Schendel
Bedrijven | Functie | Begin |
---|---|---|
MEDIGENE AG | Chief Tech/Sci/R&D Officer | 01-05-2014 |
MediGene, Inc.
MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Chief Executive Officer | - |
Eerdere bekende functies van Dolores J. Schendel
Bedrijven | Functie | Einde |
---|---|---|
Institute of Molecular Immunology | Director/Board Member | 01-01-2013 |
European Research Council
European Research Council Investment Trusts/Mutual FundsMiscellaneous The European Research Council is an organization that provides grants for research projects. The organization is based in Brussels, Belgium. As a grantee, individuals are required to submit scientific and financial reports for assessment by ERC Scientific Officers. The organization emphasizes the importance of research ethics and compliance with legislation, disciplinary norms, and protection of research subjects. The responsibility for ethics lies with the individuals conducting the research, while the formal accountability lies with the signatory of the Grant Agreement, the Host Institution. | Corporate Officer/Principal | - |
German Cancer Aid | Corporate Officer/Principal | - |
Deutsche Forschungsgemeinschaft | Corporate Officer/Principal | - |
Medigene Immunotherapies GmbH
Medigene Immunotherapies GmbH Pharmaceuticals: MajorHealth Technology Part of MediGene AG, Medigene Immunotherapies GmbH develops immunotherapy to treat cancer. The private company is based in Planegg, Germany. The German company was founded in 2013 by Thomas Blankenstein, Dolores J. Schendel. The CEO is Axel-Sven Malkomes. Medigene Immunotherapies was acquired by MediGene AG on January 27, 2014 for $13.05 million. | Chief Executive Officer | - |
Opleiding van Dolores J. Schendel
University of Wisconsin | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
MEDIGENE AG | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
MediGene, Inc.
MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Health Technology |
European Research Council
European Research Council Investment Trusts/Mutual FundsMiscellaneous The European Research Council is an organization that provides grants for research projects. The organization is based in Brussels, Belgium. As a grantee, individuals are required to submit scientific and financial reports for assessment by ERC Scientific Officers. The organization emphasizes the importance of research ethics and compliance with legislation, disciplinary norms, and protection of research subjects. The responsibility for ethics lies with the individuals conducting the research, while the formal accountability lies with the signatory of the Grant Agreement, the Host Institution. | Miscellaneous |
Institute of Molecular Immunology | |
Medigene Immunotherapies GmbH
Medigene Immunotherapies GmbH Pharmaceuticals: MajorHealth Technology Part of MediGene AG, Medigene Immunotherapies GmbH develops immunotherapy to treat cancer. The private company is based in Planegg, Germany. The German company was founded in 2013 by Thomas Blankenstein, Dolores J. Schendel. The CEO is Axel-Sven Malkomes. Medigene Immunotherapies was acquired by MediGene AG on January 27, 2014 for $13.05 million. | Health Technology |
German Cancer Aid |